FY4/23
Supplementary Materials

June 2, 2023

１．Consolidated Results■Year-on-Year(¥ million)

FY4/22
results

FY4/23
results

YoYchange

YoYchange(%)

Net sales

316,247

358,742+42,495+13.4

Gross profit

49,971

53,698+3,727

+7.5

15.8

15.0

34,832

37,694+2,862

+8.2

11.0

10.5

15,13916,004+865

+5.7

4.8

4.5

16,041

17,064+1,023

+6.4

5.1

4.8

Profit attributableto owners of parent

7,092

9,234+2,142+30.2% of net sales

2.2

2.6

Earnings pershare(¥)

201.47262.87+61.40+30.5% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

Figures in the table are rounded down

■Vs Plan(¥ million)

FY4/23
revised plan

Net sales

358,000

358,742

+742

+0.2

Gross profit

54,87053,698(1,172)

(2.1)

15.3

15.0

37,69037,694

+4

+0.0

10.5

10.5

17,18016,004(1,176)

(6.8)

4.8

4.5

18,03017,064(966)

(5.4)

5.0

4.8

Profit attributableto owners of parent

9,000

9,234+234+2.6% of net sales2.5

2.6

Earnings pershare(¥)

256.20262.87+6.67+2.6% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

Figures in the table are rounded down

FY4/23
results-1-

Vs planchangeVs planchange(%)

２. Segment Information（Dispensing Pharmacy Business）■Year-on-Year(¥ million)

FY4/22
results

FY4/23
results

YoYchange

YoYchange(%)

Net sales

283,111

321,577+38,466+13.6

Gross profit

38,194

39,779+1,585

+4.1

13.5

12.4

13,875

16,559+2,684+19.3

4.9

5.1

24,31923,220(1,099)

(4.5)

8.6

7.2

25,082

24,135(947)

(3.8)

8.9

7.5

% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Segment profit% of net sales

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the consolidated statement of income■Vs Plan(¥ million)

FY4/23
revised plan

Net sales

321,560

321,577+17+0.0

Gross profit

41,35039,779(1,571)

(3.8)

12.9

12.4

16,62016,559

(61)

(0.4)

5.2

5.124,730

23,220(1,510)

(6.1)

7.7

7.2

25,52024,135(1,385)

(5.4)

7.9

7.5

% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Segment profit% of net sales

FY4/23
results

Vs planchange

Vs planchange(%)

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the consolidated statement of income-2-3. Segment Information（Cosmetic and Drug Store Business）■Year-on-Year(¥ million)

FY4/22
results

FY4/23
results

YoYchange

YoYchange(%)

Net sales

20,55825,685+5,127+24.9

Gross profit

7,030

9,694+2,664+37.9

34.2

37.7

8,858

8,521(337)

(3.8)

43.1

33.2

▲1,827

1,172+2,999--

4.6▲1,764

1,214+2,978--4.7% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Segment profit% of net sales

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the consolidated statement of income■Vs Plan(¥ million)

FY4/23
revised planNet sales

24,92025,685+765+3.1Gross profit

9,410

9,694+284+3.0

37.8

37.7

8,570

8,521(49)(0.6)% of net sales

34.4

33.2

Operating profit840

1,172+332+39.5% of net sales

3.4

4.6

Segment profit

880

1,214+334+38.0% of net sales

3.5

4.7

% of net sales

SG&A expenses

FY4/23
results

Vs planchange

Vs planchange(%)

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the consolidated statement of income-3-4. Sales Verification■Dispensing Pharmacy Business (YoY）■Dispensing Pharmacy Business（Vs Plan）

Net sales

Net sales（%）

Average
Prescription
prescription
volumeprice（%）

Average
Prescription
prescription
volumepriceSame store (1,026)＋2.3＋2.4(0.1)

Same store (1,026)(0.1)＋0.4(0.5)

Store openings in theprevious year (49)＋77.4＋79.4(1.1)

Store openings in theprevious year (49)

(0.4)

(0.3)

(0.1)

Total (1,209)

＋13.6

＋13.5

‐

Total (1,209)(0.1)＋0.4(0.4)■Cosmetic and Drug Store Business（YoY）■Cosmetic and Drug Store Business (Vs Plan）

Net sales

Net sales（%）

Average
Number ofspending per
customers
customer（%）

Average
Number ofspending per
customers
customerSame store (58)＋18.4＋15.8＋2.3

Same store (58)＋2.7＋1.7＋1.9

Store openings in theprevious year (12)＋260.9＋247.9＋3.8

Store openings in theprevious year (12)＋3.4＋5.6＋1.6＋24.9＋22.1＋2.3

Total (78)＋2.9＋1.4＋1.5

Total (78)-4-

5. Consolidated Balance Sheet■Assets(¥ million)

End-FY4/21

End-FY4/22

End-FY4/23

Change55,271

59,72946,796(12,933)

13,475

10,11013,249+3,139

14,285

14,79021,586+6,796

96,398100,765

98,305(2,460)

Buildings and structures,net

16,27017,512

21,407+3,895Land

10,3908,581

10,602+2,02130,22930,63639,459+8,82339,05736,352

46,443+10,091

Total intangible fixed assets

42,666

41,21952,343+11,124

Investments in securities

2,697

2,503

2,720+217

Deferred tax assets

4,415

5,319

5,990

+671

Deposits and guarantees

20,31922,78524,507+1,722

Total investments and otherassets

34,36839,84041,641+1,801

Total fixed assets

107,264

111,696

133,444+21,748

Total assets

203,662

212,461

231,750

19,289Cash on hand and in banks
Notes and accounts
receivable
Inventories
Total current assets

Total property,plant andequipment
Goodwill

Figures in the table are rounded down

Change:End-FY4/23 compared with end-FY4/22
Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees)
totaled ¥14,756million■Liabilities and Net Assets(¥ million)

End-FY4/21

End-FY4/22

End-FY4/23

ChangeAccounts payable

46,75850,756

58,698+7,942

Short-term debt

3,670

2,643

3,670

+1,027

74,16081,80592,986+11,181

8,297

5,815

5,021

(794)

Total long-term liabilities

13,664

11,645

12,218+573

Total liabilities

87,82593,450105,204+11,754

Common stock

21,894

21,894

21,894-

Capital surplus

20,50020,50020,504+4Retained earnings

73,50678,661

85,963+7,302

Total shareholders’ equity

115,899

119,038

126,362+7,324

Total net assets

115,837

119,010

126,546+7,536

Total liabilities and net
assets203,662212,461

231,750+19,289

Figures in the table are rounded down

Change:End-FY4/23 compared with end-FY4/22

Total current liabilities
Long-term debt-5-6. FY4/24 Plan (Consolidated)(¥ million)
Net sales

316,247

358,742

375,000+16,258+4.5

Gross profit

49,971

53,69855,413+1,715

+3.2

15.8

15.0

14.8

34,832

37,69439,750+2,056

+5.5

11.0

10.5

10.6

15,13916,004

15,663

(341)

(2.1)

4.8

4.5

4.2

16,041

17,06416,302

(762)

(4.5)

5.1

4.8

4.3

Profit attributableto owners of parent

7,092

9,234

8,250(984)(10.7)% of net sales

2.2

2.6

2.2

Earnings pershare(¥)

201.47262.87234.84(28.03)(10.7)

Annual dividend (¥)

55.00

60.00

60.00

-0.0

% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

FY4/23
results

YoYchange

FY4/22
results

Figures in the table are rounded down
Change:FY4/24 plan compared with FY4/23 results-6-

FY4/24plan

YoYchange (%)

7. Transition of Store Openings■Number of Store Openings in Dispensing Pharmacy Business
FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22 FY4/23Organic

403227252314152527M&A1191101821113461424114Total

754

881

1,066

1,029

1,132

1,088

1,065

1,099

1,209

■Number of Store Openings in Cosmetic and Drug Store Business
FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22 FY4/23Organic

359471511128Total

565252485463697878Inquiries related to this presentation should be addressed toAIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/
This document may not be reproduced or distributed to any third party without
prior approval of AIN HOLDINGS INC. This document has been prepared for
information purpose only and does not form part of a solicitation to sell orpurchase any securities. Information contained herein may be changed orrevised without prior notice. This document may contain forecasting statements
as to future results of operations. No forecast statement can be guaranteed andactual results of operations may differ from those projected.

-7-